

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 08191-029US1	Application No. 10/532,168
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Kathleen Beach et al.	
		Filing Date March 21, 2006	Group Art Unit 1648
(37 CFR §1.98(b))			

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	4,741,872	05/03/98	DeLuca et al.			
	AB	4,777,239	10/11/88	Schoolnik et al.			
	AC	5,075,109	12/24/91	Tice et al.			
	AD	5,413,797	05/09/95	Khan et al.			
	AE	5,547,846	08/20/96	Bartsch et al.			
	AF	5,580,859	12/03/96	Felgner et al.			
	AG	5,589,466	12/31/96	Felgner et al.			
	AH	5,593,972	01/14/97	Weiner et al.			
	AI	5,629,161	05/13/97	Muller et al.			
	AJ	5,633,234	05/27/97	August et al.			
	AK	5,643,605	07/01/97	Cleland et al.			
	AL	5,648,459	07/15/97	Cole et al.			
	AM	5,656,297	08/12/97	Bernstein et al.			
	AN	5,679,509	10/21/97	Wheeler et al.			
	AO	5,679,647	10/21/97	Carson et al.			
	AP	5,695,770	12/09/97	Raychaudhuri et al.			
	AQ	5,703,055	12/30/97	Felgner et al.			
	AR	5,705,151	01/06/98	Dow et al.			
	AS	5,709,860	01/20/98	Raychaudhuri et al.			
	AT	5,719,054	02/17/98	Boursnell et al.			
	AU	5,733,548	03/31/98	Restifo et al.			
	AV	5,736,524	04/07/98	Content et al.			
	AW	5,753,233	05/19/98	Bleul et al.			
	AX	5,783,567	07/21/98	Hedley et al.			
	AY	5,840,306	11/24/98	Hofmann et al.			
	AZ	5,846,540	12/08/98	Restifo et al.			
	AAA	5,880,103	03/09/99	Urban et al.			

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AS/

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 08191-029US1	Application No. 10/532,168
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Kathleen Beach et al.	
		Filing Date March 21, 2006	Group Art Unit 1648

(37 CFR §1.98(b))

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	ABB	5,932,412	08/03/99	Dillner et al.			
	ACC	5,962,428	10/05/99	Carrano et al.			
	ADD	6,004,557	12/21/99	Edwards et al.			
	AEE	6,007,806	12/28/99	Lathe et al.			
	AFF	6,013,258	01/11/00	Urban et al.			
	AGG	6,037,135	03/14/00	Kubo et al.			
	AHH	6,183,745	02/06/01	Tindle et al.			
	AII	6,183,746	02/06/01	Urban et al.			
	AJJ	6,235,523	05/22/01	Gajewczyk et al.			
	AKK	6,248,565	06/19/01	Williams et al.			
	ALL	6,306,397	10/23/01	Edwards et al.			
	AMM	6,534,482	03/18/03	Fikes			
	ANN	6,797,491	09/28/04	Neeffe et al.			
	AOO	2002/0103145	08/01/02	Bot et al.			
	APP	2002/0164721	11/07/02	Firat et al.			
	AQQ	2005/0100928	05/12/05	Hedley et al.			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	ARR	60-147368	07/04/85	Japan				
	ASS	0 451 550 A2	10/16/91	EP				
	ATT	WO 92/05248	04/02/92	PCT				
	AUU	WO 93/22338	11/11/93	PCT				
	AVV	WO 94/03205	02/17/94	PCT				
	AWW	WO 94/04557	03/03/94	PCT				
	AXX	WO 94/20127	09/15/94	PCT				
	AYY	WO 94/21680	09/29/94	PCT				

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AS/

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 08191-029US1	Application No. 10/532,168
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Kathleen Beach et al.	
		Filing Date March 21, 2006	Group Art Unit 1648
(37 CFR §1.98(b))			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AZZ	WO 94/23738	10/27/94	PCT				
	AAAA	WO 95/24929	09/21/95	PCT				
	ABBB	WO 96/00583	01/11/96	PCT				
	ACCC	WO 96/03144	02/08/96	PCT				
	ADDD	WO 96/19496	06/27/96	PCT				
	AEEE	WO 97/17063	05/15/97	PCT				
	AFFF	WO 97/33602	09/18/97	PCT				
	AGGG	WO 97/34617	09/25/97	PCT				
	AHHH	WO 97/41440	11/06/97	PCT				
	AIII	WO 97/42940	11/20/97	PCT				
	AJJJ	WO 98/31398	07/23/98	PCT				
	AKKK	WO 99/18995	04/22/99	PCT				
	ALLL	WO 99/45954	09/16/99	PCT				
	AMMM	WO 99/58658	11/18/99	PCT				
	ANNN	WO 00/75336	12/14/00	PCT				
	AOOO	WO 01/41799	06/14/01	PCT				
	APPP	WO 01/19408	03/22/01	PCT				

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AQQQ	An et al. "A Multivalent Minigene Vaccine, Containing B-Cell, Cytotoxic T-Lymphocyte, and T _H Epitopes from Several Microbes, Induces Appropriate Responses In Vivo and Confers Protection Against More Than One Pathogen" J. VIROLOGY, 71(3):2292-2302 (1997)
	ARRR	Boursnell et al., <i>Construction and characterization of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer</i> , Vaccine, 1996, Vol. 14, No. 16, pp. 1485-1494.
	ASSS	Cohen et al. <i>HIV/AIDS in 1998 - Gaining the Upper Hand?</i> , JAMA, Vol. 280, No. 1:87-88 (1998).
	ANNN	Collins et al., "Processing Of Exogenous Liposome-Encapsulated Antigens In Vivo Generates Class I Mhc-Restricted T Cell Responses," THE JOURNAL OF IMMUNOLOGY, 148:3336-3341, No. 11, June 1, 1992
	AUUU	Cryz et al., <i>Vaccine Delivery Systems</i> , Vaccine, Vol. 14:p. 665-690, Vol. 14 (1996).

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AS/

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 08191-029US1	Application No. 10/532,168
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Kathleen Beach et al.	
		Filing Date March 21, 2006	Group Art Unit 1648
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	APPP	Donahoe et al. "Direct Measurement of CD8+ T Cell Responses In Macaques Infected With Simian Immunodeficiency Virus" VIROLOGY, 272:347-356 (2000)
	AWWW	Donnelly et al., "Immunization with DNA," JOURNAL OF IMMUNOLOGICAL METHODS, 176:145-152, No. 2 (1994)
	AXXX	Elliott et al., "Processing of Major Histocompatibility Class I-restricted Antigens in the Endoplasmic Reticulum," THE JOURNAL OF EXPERIMENTAL MEDICINE, 181:1481-1491 (1995)
	AYYY	Feltkamp et al., "Vaccination with cytotoxic T Lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells," EUROPEAN JOURNAL OF IMMUNOLOGY, 23:2242-2249 (1993)
	AZZZ	Fries et al., "Liposomal Malaria Vaccine in Humans: A Safe and Potent adjuvant Strategy," PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, 89:358-362 (1992)
	AAAAA	Fynan et al., "DNA Vaccines: Protective Immunizations by Parenteral, Mucosal, and Gene-Gun Inoculations," PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, 90:11478-11482 (1993)
	ABBBB	Gao et al., "Tumor-Associated E6 Protein of Human Papillomavirus Type 16 Contains an Unusual H-2K [*] -Restricted Cytotoxic T Cell Epitope," THE JOURNAL OF IMMUNOLOGY, 155:5519-5526 (1995)
	ACCCC	Garcia et al., "ZYG101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial," Obstet. Gynecol., 103:317-326 (2004)
	ADDDD	Hanke et al. "DNA Multi-CTL Epitope Vaccines for HIV and <i>Plasmodium Falciparum</i> : Immunogenicity In Mice" VACCINE, 16(4):426-435 (1998)
	AEEEE	Hanke et al. "Effective Induction of HIV-Specific CTL By Multi-Epitope Using Gene Gun In a Combined Vaccination Regime" VACCINE, (17):598-596 (1999).
	AFFFF	Hanke et al. "Immunogenicities of Intravenous and Intramuscular Administrations of Modified Vaccinia Virus Ankara-Based Multi-CTL Epitope Vaccine for Human Immunodeficiency Virus Type 1 In Mice" J. GENERAL VIROLOGY, 79:83-90 (1998).
	AGGGG	Hanke et al. "Pre-Clinical Development of a Multi-CTL Epitope-Based DNA Prime MVA Boost Vaccine for AIDS" IMMUNOLOGY LETTERS, 66:177-181 (1999).
	AHHHH	Hedley et al., <i>Microspheres Containing Plasmid-Encoded Antigens Elicit Cytotoxic T-Cell Responses</i> , NATURE MEDICINE 4(3):365-368 (1998)
	AIIII	Hertenbach et al., "Prevention of Autoimmune Diabetes in Non-Obese Diabetic Mice by Treatment with a Class II Major Histocompatibility Complex-blocking Peptide," THE JOURNAL OF EXPERIMENTAL MEDICINE, 177:1499-1504 (1993)
	AJJJJ	Ishioaka et al. "Utilization of MHC Class I Transgenic Mice for Development of Minigene DNA Vaccines Encoding Multiple HLA-Restricted CTL Epitopes" J. IMMUNOL., 162:3915-3925 (1999)
	AKKKK	Jochmus et al., "Specificity of human cytotoxic T Lymphocytes induced by a human papillomavirus type 16 E7-derived peptide," THE JOURNAL OF GENERAL VIROLOGY, 78:1689-1695 (1997)
	ALLLL	Kadish et al., "Cell-mediated immune responses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific," THE JOURNAL OF GENERAL VIROLOGY, 75:2277-2284, September 1994
	AMMMM	Kadish et al., "Lymphoproliferative Responses to Human Papillomavirus (HPV) Type 16 Proteins E6 and E7: Outcome of HPV Infection and Associated Neoplasia," JOURNAL OF THE NATIONAL CANCER INSTITUTE, 89:1285-1293 (1997)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 08191-029US1	Application No. 10/532,168
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Kathleen Beach et al.	
		Filing Date March 21, 2006	Group Art Unit 1648
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	ANNNN	Kast "Role of HLA-A Motifs in Identification of Potential CTL Epitopes in Human Papillomavirus Type 16 E6 and E7 Proteins" <i>J. IMMUNOL.</i> , 152:3904-3912 (1994)
	AOOOO	Kast et al., "Human Leukocyte Antigen-A2.1 Restricted Candidate Cytotoxic T Lymphocyte Epitopes of Human Papillomavirus Type 16 E6 and E7 Proteins Identified by Using the Processing-Defective Human Cell Line T2," <i>THE JOURNAL OF IMMUNOTHERAPY</i> , 14:115-120 (1993)
	APPPP	Klencke et al., "Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a phase I study of ZYC101," <i>Clinical Cancer Research</i> , 8:1028-1037 (2002)
	AQQQQ	Lalvani "An HLA-Based Approach To the Design Of a CTL-Inducing Vaccine Against <i>Plasmodium Falciparum</i> " <i>RES. IMMUNOL.</i> , 145(6):461-468 (1994)
	ARRRR	Lin et al., "Treatment of Established Tumors with a Novel Vaccine that Enhances Major Histocompatibility Class II Presentation of Tumor Antigen," <i>CANCER RESEARCH</i> , 56:21-26 (1996).
	ASSSS	Madden et al., "The Antigenic Identity of Peptide-MHC Complexes: A Comparison of the conformations of Five Viral Peptides Presented by HLA-A2," <i>CELL</i> , 75:693-708 (1993)
	ATTTT	Moscicki, A.B., <i>Human Papillomavirus Infection In Adolescents</i> , PEDIATRIC CLINICS OF NORTH AMERICA, 46(4):783-807 (1999).
	AUUUU	McCluskie et al., <i>Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates</i> , pp. 287-300 (1999)
	AVVVV	McKenzie, <i>Immunologic Res.</i> 24/3:225-244 (2001)
	AWWWW	Mowat et al., "ISCOMS - A Novel Strategy for Mucosal Immunization?", <i>IMMUNOLOGY TODAY</i> , 12:383-385 (1991)
	AXXXX	Murakami et al., <i>Human Papillomavirus Vaccines for Cervical Cancer</i> , <i>Journal of Immunotherapy</i> , Vol. 22:3, pp. 212-218 (1999).
	AYYYY	Nabel et al., "Transduction of a Foreign Histocompatibility Gene into the Arterial Wall Induces Vasculitis," <i>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES</i> , 89:5157-5161, No. 11 (1992).
	AZZZZ	Nixon et al. "Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes and Protection Against Challenge In Rhesus Macaques Immunized With a Live Attenuated Simian Immunodeficiency Virus Vaccine" <i>VIROLOGY</i> , 266:203-210 (2000).
	AAAAAA	Osband et al., "Problems in the Investigational Study and Clinical Use of Cancer Immunotherapy," <i>IMMUNOLOGY TODAY</i> , 11:193-195 (1990)
	ABBBBB	Pachuk et al., <i>DNA Vaccines-Challenges in Delivery</i> , <i>Current Opinion in Molecular Therapeutics</i> , Vol. 2, No. 2, pp. 188-198. (2000)
	ACCCCC	Piscitelli, <i>Immune-Based Therapies for Treatment of HIV Infection</i> , <i>The Annals of Pharmacotherapy</i> , Vol. 30:62-76 (1996).
	ADDDDD	Reddy et al., "In Vivo Cytotoxic T Lymphocyte Induction with Soluble Proteins Administered in Liposomes," <i>THE JOURNAL OF IMMUNOLOGY</i> , 148:1585-1589, No. 5 (1992).
	AEEEEEE	Ressing et al., "Human CTL Epitopes Encoded by Human Papillomavirus Type 16 E6 and E7 Identified Through In Vivo and In Vitro Immunogenicity Studies of HLA-A 0201 Binding Peptides," <i>THE JOURNAL OF IMMUNOLOGY</i> , 154:5934-5943 (1995).
	AFFFFF	Ressing et al., "Occasional Memory Cytotoxic T-Cell Responses of Patients with Human Papillomavirus Type 16-positive Cervical Lesions against a Human Leukocyte Antigen-A 0201-restricted E7-encoded Epitope," <i>CANCER RESEARCH</i> , 56:582-588 (1996).

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AS/

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 08191-029US1	Application No. 10/532,168
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Kathleen Beach et al.	
		Filing Date March 21, 2006	Group Art Unit 1648
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AGGGGC	Sheets et al., "Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA," American J. of Obstet. Gynecol. 188:916-926 (2003).
	AHHHHH	Shrine et al., "Pangaea Aims Naturally Processed Peptides at First viral Target: Human Papilloma Virus," BIOWORLD TODAY, THE BIOTECHNOLOGY NEWSPAPER, 7:1-2 (1996).
	AIIIII	Stellar et al., "Human Papillomavirus Immunology and Vaccine Prospects," JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, No. 21, pp. 145-148 (1996).
	AJJJJJ	Suhrbier "Multi-Epitope DNA Vaccines" IMMUNOL. CELL BIOL., 75:402-408 (1997).
	AKKKKK	Takahashi et al., "Induction of CD8 Cytotoxic T Cells by Immunization with Purified HIV-1 Envelope Protein in ISCOMs," NATURE, 344:873-875 (1990).
	ALLLLL	Tarpey et al., "Human Cytotoxic T Lymphocytes Stimulated by Endogenously processed human papillomavirus type 11 E7 recognize a peptide containing a HLA-A2 (A*0201) motif," IMMUNOLOGY, 81:222-227 (1994).
	AMMMMM	Thomson et al., "Delivery of Multiple CD8 Cytotoxic T Cell Epitopes by DNA Vaccination" J IMMUNOL., 160:1717-1723 (1998).
	ANNNNN	Thomson et al., "Minimal Epitopes Expressed In a Recombinant Polyepitope Protein Are Processed and Presented to CD8 ⁺ Cytotoxic T Cells: Implications for Vaccine Design" PROC. NATL. ACAD. SCI., 92:5845-5849 (1995).
	AOOOOO	Thomson et al., "Recombinant Polyepitope Vaccines for the Delivery of Multiple CD8 Cytotoxic T Cell Epitopes" J. IMMUNOL., 157:822-826 (1996).
	APPPPP	Toes et al., "Protective Anti-Tumor Immunity Induced by Vaccination With Recombinant Adenoviruses Encoding Multiple Tumor-Associated Cytotoxic T Lymphocyte Epitopes In a String-of-Beads Fashion" PROC. NATL. ACAD. SCI., 94:14660-14665 (1997).
	AQQQQQ	Teukui et al., "Interleukin 2 Production in vitro by Peripheral Lymphocytes in response to Human Papillomavirus-derived peptides: Correlation with Cervical Pathology," CANCER RESEARCH, 56:3967-3974 (1996).
	ARRRRR	Urban et al., "A subset of HLA-B27 Molecules contains peptides much longer than nonamers," PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, 91:1534-1538 (1994).
	ASSSSS	Vitiello et al., "Analysis of the HLA-restricted Influenza-specific Cytotoxic T Lymphocyte Response in Transgenic Mice Carrying a Chimeric Human-Mouse Class I Major Histocompatibility Complex," THE JOURNAL OF EXPERIMENTAL MEDICINE, 173:1007-1015 (1991).
	ATTTTT	Vitiello et al., "Development of a Lipopeptide Based Therapeutic Vaccine to Treat Chronic HBV Infection," THE JOURNAL OF CLINICAL INVESTIGATION, 95:341-349 (1995).
	AUUUUU	Von Heijne, Gunnar, "A New Method for Predicting Signal Sequence Cleavage Sites", NUCLEIC ACIDS RESEARCH, 14(11):4683-4690 (1986).
	AVVVVV	Whitton et al., "A "String-of-Beads" Vaccine, Comprising Linked Minigenes, Confers Protection From Lethal-Dose Virus Challenge" J. VIROLOGY, 67(1):348-352 (1993).
	AWWWWW	Zhu et al., "Both Immunization with Protein and Recombinant Vaccinia Virus Can Stimulate CTL Specific for the E7 Protein of Human Papilloma Virus 16 in H-2 ^d Mice," SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 42:557-563 (1995).

Examiner Signature /Ali Salimi/	Date Considered 07/02/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	